drugset / Trial / NCT03414450
Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies
Phase 1
Withdrawn
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Chiltern International Inc. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This study evaluates the use of ETC-1907206 in combination with dasatinib in certain types of blood cancers. The first phase of the study (1A) is designed to find the highest tolerated dose of ETC-1907206, while the second phase (1B) will assess the safety and tolerability of the recommended dose of ETC-1907206. ETC-1907206 has been designed to block the activity of an enzyme of the body known as Mnk kinase, which is thought to be involved in the development of a variety of cancers.
Timeline
- Start
- 2018-04-25
- Primary completion
- 2022-02
- Completion
- 2023-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tinodasertib | Small molecule | 10 mg | Oral |
| Subject | Tinodasertib | Small molecule | 50 mg | Oral |
| Subject | dasatinib anhydrous | Small molecule | 140 mg | Oral |